Related references
Note: Only part of the references are listed.Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling
Nicholas R. Anderson et al.
LEUKEMIA (2023)
The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies
Mahdieh Mehrpouri
EUROPEAN JOURNAL OF PHARMACOLOGY (2022)
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development
Yiyi Yao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Role of CXCR4 in the progression and therapy of acute leukaemia
Long Su et al.
CELL PROLIFERATION (2021)
Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia
Eleni E. Ladikou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
Ashraf Mousavi
IMMUNOLOGY LETTERS (2020)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia
Zinat Yazdani et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Phase 1 study of combinatorial sorafenib,G-CSF, and plerixafor treatment in relapsed/refractory,FLT3-ITD-mutated acute myelogenous leukemia patients
Gautam Borthakur et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
Bo-Reum Kim et al.
CANCERS (2020)
Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia
Jie Meng et al.
SMALL (2020)
Novel Approaches to Target Mutant FLT3 Leukaemia
Joerg P. Mueller et al.
CANCERS (2020)
FMS-LIKE TYROSINE KINASE 3/FLT3: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS
Julhash U. Kazi et al.
PHYSIOLOGICAL REVIEWS (2019)
Prognostic significance of CXCR4 expression in acute myeloid leukemia
Wen Du et al.
CANCER MEDICINE (2019)
The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia
Tingyong Cao et al.
SCIENTIFIC REPORTS (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
M. Abraham et al.
LEUKEMIA (2017)
FLT3-ITD and its current role in acute myeloid leukaemia
Francisco Alejandro Lagunas-Rangel et al.
MEDICAL ONCOLOGY (2017)
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition
Ellen L. Weisberg et al.
ONCOTARGET (2017)
CXCR4 signaling in health and disease
Tommaso Pozzobon et al.
IMMUNOLOGY LETTERS (2016)
Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies
Xiaoli Wu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
Amnon Peled et al.
THERANOSTICS (2013)
The Prognostic Value of CXCR4 in Acute Myeloid Leukemia
Jeong Yeal Ahn et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts
Angela Jacobi et al.
EXPERIMENTAL HEMATOLOGY (2010)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration
Rebekka Grundler et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
J. A. Burger et al.
LEUKEMIA (2009)
CXCR4 in acute myelogenous leukemia (AML): When too much attraction is bad for you
Jan A. Burger
LEUKEMIA RESEARCH (2009)
Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia
Emmanuelle Tavernier-Tardy et al.
LEUKEMIA RESEARCH (2009)
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
Sergej Konoplev et al.
CANCER (2007)
CXCR4 is a prognostic marker in acute myelogenous leukemia
Anke C. Spoo et al.
BLOOD (2007)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
R Grundler et al.
BLOOD (2005)
FIG ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1α(CXCL12)/CXCR4 axis
S Fukuda et al.
BLOOD (2005)
Incorporation of CXCR4 into membrane hpid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient
M Wysoczynski et al.
BLOOD (2005)
CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice
S Tavor et al.
CANCER RESEARCH (2004)
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia
EJC Rombouts et al.
BLOOD (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
M Mizuki et al.
BLOOD (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
Share Paper
